Genetic Markers Predicting Response to Clostridium difficile Toxin B Treatments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections (CDI) often fail to prevent recurrence, and there is a need for a method to identify patients who would benefit from therapies targeting C. difficile toxin B, such as the antibody bezlotoxumab, to improve treatment efficacy and reduce costs.
Innovation Solution
Genetic markers on human chromosome 6, including specific single nucleotide polymorphisms (SNPs) and HLA alleles, are used to predict response to treatments targeting C. difficile toxin B, allowing for personalized treatment approaches by identifying patients likely to benefit from bezlotoxumab or similar medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic markers are used to identify patients likely to benefit from bezlotoxumab treatment, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The diagnostic process is segmented into specific steps: obtaining a biological sample, extracting and amplifying DNA, detecting specific SNP genotypes (rs2516513, rs113379306, rs76166871), and comparing results to reference values. This segmentation transforms a complex diagnostic challenge into manageable, standardized procedures that can be systematically implemented.
Solution Approach 2:
The invention changes the diagnostic parameter from general clinical assessment to specific genetic marker detection. By focusing on particular SNP genotypes at defined chromosomal locations, the diagnosis transitions from subjective clinical judgment to objective molecular measurement, improving reliability while maintaining manageable complexity through targeted analysis.
2Reliability
If bezlotoxumab treatment is administered to all CDI patients, then recurrence prevention coverage is improved, but treatment cost increases
Solution Approach 1:
The treatment approach transitions from universal administration to targeted delivery based on local genetic characteristics. Patients are stratified into high-risk groups identified by specific genotype patterns, allowing bezlotoxumab to be administered locally to those who will benefit most, rather than universally to all CDI patients. This local quality approach optimizes both coverage and cost-effectiveness.
Solution Approach 2:
Instead of treating all patients (excessive action), the invention applies partial treatment only to the subset of patients with high-risk genotypes. This partial action approach avoids unnecessary treatment costs for low-risk patients while maintaining adequate prevention coverage for those who need it most, achieving cost-effectiveness without sacrificing essential protection.
Data Source
AI summary
The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets Clostridium difficile (C. difficile) toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment that targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.